Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13 Urinary Bladder Neoplasms 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Neoplasm Metastasis 1 Lung Neoplasms 1 Glioblastoma 1 Genomic Instability 1 Carcinoma, Hepatocellular 1 Biliary Tract Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1 Adenocarcinoma of Lung 1 ALK-positive NSCLC 1 ALK+ Advanced NSCLC 1 ALK Gene Rearrangement Positive 1

Interventions

Carboplatin 8 Paclitaxel 7 Gemcitabine 7 Irinotecan 6 Radiotherapy 4 Oxaliplatin 4 Capecitabine 4 Leucovorin 3 Fluorouracil 3 Filgrastim 3 Erlotinib Hydrochloride 3 Cisplatin 3 Bevacizumab 3 etoposide phosphate 2 Trastuzumab 2 Surveys and Questionnaires 2 Peripheral Blood Stem Cell Transplantation 2 Etoposide 2 Amifostine 2 Albumin-Bound Paclitaxel 2 tipifarnib 1 tegafur-gimeracil-oteracil 1 sintilimab 1 pertuzumab 1 pemigatinib 1 pembrolizumab 1 olaparib 1 ivosidenib 1 ipatasertib 1 erythromycin propionate-N-acetylcysteinate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoplasms, Unknown Primary × alectinib × Clear all

NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡